ContraFect Corp (CFRXQ)

ContraFect Corp is a common stock listing on OTC Markets tied to a clinical-stage biotechnology company focused on therapeutic proteins and antibodies for serious infectious diseases. Its development pipeline has included Exebacase, a lysin in late-stage testing for Staphylococcus aureus, along with CF-370, an antibacterial candidate in early clinical development for Pseudomonas aeruginosa-related infections, and CF-296, an engineered lysin being studied for invasive staphylococcal infections, including joint and device-related cases. The company has also reported work on Exebacase for persistent MRSA bacteremia in COVID-19 patients and has a license agreement with Rockefeller University related to novel lysin candidates targeting gram-negative pathogens. ContraFect was incorporated in 2008 and is based in Yonkers, New York. In December 2023, it filed for voluntary liquidation under Chapter 7 in the U.S. Bankruptcy Court for the District of Delaware.

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.